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© 2015 Elsevier B.V. All rights reserved.1. Overview of the NCLs and the need for treatment
The neuronal ceroid lipofuscinoses (NCLs, Batten disease) are a
group of severe primarily autosomal recessive and incurable childhood
lysosomal storage disorders (LSDs). They have a combined incidence of
1 in 12,500 live births, affectingmales and femaleswith equal frequency
[26,74]. There are at least 13 distinct forms of NCL caused by mutations
in different genes (Table 1) [27]. The NCLs are among themost common
neurodegenerative disorders of childhood; characterised by severe cor-
tical atrophy, visual impairment, seizures, personality and behavioural
changes, dementia, and regression in communication and motor skills,
culminating in premature death [46].
In young children, NCL results from mutations in genes CLN1
through CLN14, excluding adult onset CLN4, 11 and 13 (NCL mutation
database; http://www.ucl.ac.uk/ncl/). Although all childhood forms of
the disease share common features, there is also substantial clinical var-
iation based on the affected gene and speciﬁc mutations. For example,
CLN2mutations cause typical progressive myoclonus epilepsy, whereas
CLN3 mutations produce cognitive and motor decline over most of the
disease course with mild myoclonus and epilepsy at later stages [73].
Historically, each mutation in an NCL associated gene was believed toesearch on theNeuronal Ceroid
y, University of Otago, P.O. Box
ughes).cause the sameNCL disease variant, i.e., CLN1mutations caused infantile
NCL, CLN2 mutations; late infantile NCL and so on. However, with ad-
vances in genetic screening technology, it has become clear that muta-
tions in an NCL-associated gene may lead to numerous overt NCL
disease subtypes. This is especially well characterised in the CLN1
gene, wheremutations have been identiﬁed in cases of infantile, late in-
fantile, juvenile, and adult NCL [43] with age of onset correlating with
level of residual enzyme activity.
Lysosomal diseases affecting the brain present signiﬁcant difﬁculties
for treatment. Historically trialled techniques, such as peripherally-
administered enzyme replacement therapy (ERT), have shown limited
success for treating CNS disease. Other strategies, such as chaperone
therapy, gene therapy, CNS-administered ERT and cell mediated thera-
py show promise in their ability to impact upon the CNS (Fig. 1). How-
ever these approaches remain largely experimental.
This schematic outlines the experimental therapeutic strategies pre-
sented in this review, highlighting the major routes of administration,
either direct brain or ventricle injection (grey) or intravenous/intra-
muscular or oral (blue). Small molecule therapies are administered in-
travenously, intramuscularly, or orally. The potential for development
of orally available formulationsmakes these therapies non-invasive. En-
zyme replacement therapies involve intracerebroventricular adminis-
tration. Stem cell therapies and gene therapies differ in terms of
administration route depending on the type of stem cell or viral vector
used. Bone marrow transplants and AAV vectors can be administered
systemically, whilst neural progenitor cells and lentiviral vectors are ad-
ministered directly to the brain or ventricles. AAV therapies are often
administered into the CNS.
Table 1
Summary of the NCL diseases.
Disease
form
Clinical phenotype Presenting symptom Gene/locus Protein name Cellular
localisation
CLN1 Infantile classic, late infantile, juvenile, adult Cognitive and motor
decline, vision loss
CLN1, 1p34.2 PPT1 Lysosomal
lumen
CLN2 Late infantile classic, juvenile Seizures and ataxia CLN2, 11p15.4 TTP1 Lysosomal
lumen
CLN3 Juvenile classic Visual failure CLN3, 16p11.2 CLN3 Lysosomal
membrane
CLN4 Adult autosomal dominant Myoclonic epilepsy CLN4, 20q13.33 DNAJC5 Synaptic vesicles
CLN5 Late infantile variant, juvenile, adult Motor clumsiness CLN5, 13q22.3 Unknown Lysosomal
lumen
CLN6 Late infantile variant, adult (Kufs type A) Motor problems and
seizures
CLN6, 15q23 Unknown ER membrane
CLN7 Late infantile variant, juvenile, adult Cognitive and motor
decline
CLN7, 4q28 MFSD8 Lysosomal
membrane
CLN8 Late infantile variant, progressive epilepsy with
mental retardation
Epileptic seizures CLN8, 8p23.3 Unknown ER–Golgi
membrane
CLN10 Congenital classic, late infantile, adult Seizures CLN10/CTSD,
11p15.5
Cathepsin D Lysosomal
lumen
CLN11 Adult Visual failure and seizures CLN11, 17q21.31 Progranulin (GRN) Secretory
pathway
CLN12 Juvenile, Kufor-Raheb syndrome Learning difﬁculties CLN1/ATP13A2,
1p36.13
ATPase Type 13A2 Lysosomal
membrane
CLN13 Adult Kufs type Dementia and motor
disturbances
CLN13/CTSF,
11q13.2
Cathepsin F Lysosomal
lumen
CLN14 Infantile, progressive myoclonus epilepsy 3 Seizures CLN14/KCTD7,
7q11.21
Potassium channel tetramerist-ion
domain-containing protein 7 (KCTD7)
Intracytoplasmic
Adapted from www.ucl.ac.uk/ncl.
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ment of NCL. Patient care is focused onminimising symptoms, including
seizures, behavioural problems, and depression. Physical and occupa-
tional therapies are routinely used to aid in the retention of physical
abilities [80]. Some experimental treatments result in mild improve-
ments but none have been able to halt disease progression or signiﬁ-
cantly improve quality or duration of life.
Therapies relying on the correction or replacement of the faulty pro-
tein require expression of the corrected protein to be sustained within
the brain, without any associated toxicity, for long-term treatment.
These prerequisites represent a formidable challenge for therapy de-
sign. However, LSD therapy generally requires an achievable 5–15% res-
toration of normal enzyme activity to restore normal function [18,48,
79].
This review focuses on recent developments in the search for
effective NCL treatments. The studies outlined in this review do not
provide a comprehensive list of all current investigative therapies butSmall molecule therapy
•  Pharmacological chaperone
•  Substrate reduction
•  Immune modulation
•  Receptor modulation
Stem cell therapy
•  Bone marrow transplants
•  Neural progenitor cells
Fig. 1. Experimental therapies tarrather highlight promising examples in each major category of clinical
investigation.
2. The importance of animal models in therapeutic development
2.1. Small animal models
Mice have been the primary model organism for investigating NCL
pathogenesis. Currently, there are ten mouse models, either genetically
developed (CLN1/PPT1 (twomodels), CLN2/TPP1, CLN3 (threemodels),
CLN5, and CLN10/CTSD), or spontaneous naturally-occurring models
(CLN6/nclf and CLN8/mnd) thus representing each of the major forms
of humanNCL aswell as a number of variant forms [15]. Eachmodel ex-
hibits key pathological features of their human counterparts, including
autoﬂuorescent cellular storage and progressive neurodegeneration
[15]. Murine studies have focused on behavioural, pathological, cellular,
and molecular abnormalities, as well as the development andEnzyme replacement therapy
•  PPT1
•  TPP2
Gene therapy
•  AAV
•  LV
get sites for administration.
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signiﬁcant heterogeneity underlying the NCL phenotypes.2.2. Large animal models
Large animalmodels of theNCLs offer a number of signiﬁcant advan-
tages over their smallmodel counterparts. The size and anatomyof their
brain aremore human-like than themurine equivalents. For example, a
mouse brain weighs about 0.5 g, a rat brain 1.9 g, and a human child at
5 years old, 450 g. This difference becomes even more signiﬁcant when
taking into consideration the fact that rodents possess lisencephalic
brains lacking gyri and sulci. Dog and sheep models bridge this large
gap in anatomy between rodents and human, both having
gyrencephalic brains of approximately 70 g (dog) and 175 g (sheep).
These large animals have a longer life expectancy, particularly useful
in investigations of the long-term treatment effects. In addition, the
clinical progression in larger animals more closely resembles that seen
in human patients. Domestic animals, such as sheep, also have the ad-
vantage of being economic to maintain and bred for easy management,
with a high level of understanding in reproductive technology and vet-
erinary care available.
Spontaneously occurring NCLs in larger animals have been reported
in ovine [8,14,34,95], bovine [28,59], equine [42,96], and canine species
[3,4,33,38,42,66,93]. The size of thesemodels leads to particular interest
in therapeutic investigations, where the biodistribution of potential
therapeutics can bemonitored over an area and anatomical layout high-
ly comparable to humans. Like the human condition, where applicable,
these animal models also accumulate subunit c of mitochondrial
ATPase, constituting 50% of the storage material in South Hampshire
sheep, Devon cow, English setters, Border collies, and Tibetan terriers
[32].
Naturally occurring ovine and canine models are routinely used in
NCL research (Table 2). Preclinical investigations of potential therapeu-
tic approaches must show success and safety in animal models of dis-
ease prior to advancement into human clinical investigation [19,68].
Using such models, a number of promising therapeutic avenues have
been developed, including (but not limited to) adeno-associated vial
(AAV) and lentiviral (LV)-mediated gene therapies, enzyme replace-
ment therapies (ERT), stem cell therapies (including bone marrow
transplantation), and small molecule therapies.3. Promising therapeutic developments
3.1. Small molecule therapy
Successful treatment of the NCLs may not rely solely on restoration
of the defective protein (as is the idea behind gene therapy and ERT).
By enhancing activity through defective signalling or metabolic path-
ways in the affected cells, restoration of adequate cellular function
may be restored, thereby alleviating disease pathology.Table 2
Established large animal models of the NCLs and their use in preclinical therapy
development.
NCL
subtype
Large animal models Use in pre-clinical trials
CLN1 Canine (miniature Dachshund) –
CLN2 Canine (long-haired
Dachshund)
AAV-mediated gene therapy, ERT [98]
CLN3 Porcine in development [68] –
CLN5 Ovine (Borderdale) AAV and LV-mediated gene therapy
CLN6 Ovine (South Hampshire,
Merino)
AAV and LV-mediated gene therapy
[53]
CLN8 Canine (English setter) –
CLN10 Ovine (Swedish landrace) –Small molecule therapies, involving the administration of various
drug compounds, can be broken down into a number of classes includ-
ing pharmacological chaperones, substrate reduction therapies, recep-
tor modulators, and immune modulators.
A strong advantage of small molecule therapeutic approaches is the
potential for non-invasive methods of drug delivery, with the potential
for the development of oral formulations. This provides an attractive al-
ternative to invasive surgical procedures.
3.1.1. Pharmacological chaperones
Although chaperone mediated small molecule therapies have not
yet reached the clinical stages of development, they have shown prom-
ise in in vitro cell culture studies.
NCL-associated point mutations generate misfolded proteins that
are recognised by ER quality control systems, resulting in the degrada-
tion of the protein before folding and trafﬁcking. Although misfolded,
proteins with a single point mutation often retain functionality, mean-
ing that avoidance of quality control systems may restore function to
the cell. Pharmacological chaperones (PC) are small molecules designed
to circumvent this problem by selectively binding to and stabilising the
mutated protein. This prevents premature degradation, allowing the
protein to fold and complete posttranslationalmodiﬁcation and trafﬁck-
ing processes, and increasing cellular activity [97].
PCs show promise where other therapies have failed. Their lowmo-
lecular weight gives them the potential to be orally available with a
broad biodistribution, which, importantly, includes the CNS. PCs are
under investigation as a NCL therapeutic. Initial in vitro experimenta-
tion, in CLN1 patient-derived lymphoblast cell culture, demonstrated a
two-fold enhancement of PPT1 activity upon addition of a PC acting as
a PPT1 inhibitor, CS38. A similar two-fold PPT1 stimulation was found
using another inhibitor in lymphoblast's derived from patients with a
different common mutation [17].
PC therapy could be used to correct the misfolding of both soluble
and membrane-bound proteins, therefore they have the potential to
be useful in the treatment of all NCL variants. However, this technique
would only be effective in the treatment of patients who carrymissense
mutations that are away from the enzyme active site, and hence would
not beneﬁt all patients.
In addition, the in vitro PC experiments described utilised molecules
unlikely to pass through the BBB.
3.1.2. Receptor modulators
Glutamate antagonists have been successfully used in the treatment
of seizures, Alzheimer's disease and Parkinson's disease [41]. The altered
expression of genes involved in glutamate metabolism was originally
reported in a CLN3−/− mouse model [69]. The mice showed an in-
creased sensitivity to AMPA receptor-mediated excitotoxicity, present-
ing the hypotheses that disease presentation was due to increased
AMPA receptor activity. The non-competitive AMPA antagonist, EGIS-
8332, was used to attenuate AMPA activity resulting in an immediate
and signiﬁcant improvement of one-month old CLN3−/− mice to a
level comparable to that of WT counterparts [44]. When administered
to a 6–7month oldmouse there was a delayed, yet prolonged improve-
ment, suggesting that temporary inhibition of AMPA receptors can in-
duce a prolonged motor-skilled correction [45]. Although promising,
receptor attenuation has yet to show signiﬁcant effects on glial activa-
tion and neuronal loss.
3.1.3. Substrate reduction therapy
Clinical studies have recently been completed looking at the com-
bined effectiveness of cysteamine bitartrate and N-acetylcysteine for
the treatment of INCL (ClinicalTrials.gov identiﬁer NCT00028262). Pa-
tients displayed a signiﬁcant decrease of granular osmiophilic deposits
(GRODs) in peripheral leukocytes as well as improved function, behav-
iour and decreased seizure frequency. Although promising, these
changes appeared to have no signiﬁcant effect on overall disease
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trial completion due to reported behavioural improvement. These trials
have shown no, or very little, evidence that removal of storage material
correlates with clinical beneﬁt or a halt of neuronal loss [15,24,49]. His-
topathological studies have also shown that regions displayingmost ex-
tensive storage do not correlate directly with neuronal loss [2,65].
3.1.4. Immune modulators
Ahallmark feature in variousNCL subtypes (both animalmodels and
humans) is widespread neuroinﬂammation resulting from activation of
astrocytes and microglia. This neuroinﬂammation develops prior to
neurodegeneration. Anti-inﬂammatory compounds provide an attrac-
tive therapeutic option to prevent or halt both neuroinﬂammation and
degeneration. To this end, the anti-inﬂammatory antibiotic,
minocycline, was administered chronically to presymptomatic South
Hampshire CLN6-affected lambs at an oral dose of 25 mg minocycline/
kg/day from the age of three to 14 months of age. It was hoped that
this daily treatment regime would be sufﬁcient to suppress neuroin-
ﬂammation and/or suppress disease progression. The minocycline was
absorbed and maintained at pharmacological concentrations in the
brain.However, it did not lead to the inhibition of astrocyte ormicroglial
activation and did not prevent neuronal loss or alter the clinical course
[39].
The presence of autoantibodies has been detected in mouse and
human JNCL patients [10,50]. Studies, using sera derived from a
CLN3−/− mouse model or JNCL patients, showed an inhibitory effect
on glutamate metabolism brought about by autoantibodies against
glutamic acid decarboxylase (GAD65), as well as the production of a
wide range of other brain-directed autoantibodies [50]. Subsequent im-
mune suppression, with mycophenolate mofetil, resulted in a decrease
of circulating autoantibodies directed towards brain antigens [82].
These studies are the basis for a phase 1 clinical trial ‘Cellcept for Treat-
ment of Juvenile Neuronal Ceroid Lipofuscinosis’ (ClinicalTrials.gov
identiﬁer NCT01399047).
3.2. Enzyme replacement therapy
Enzyme replacement therapy relies on a cross-correction approach.
The principle is that exogenous administration of the required enzyme
should have a therapeutic effect [103] via receptor-mediated uptake of
the enzyme from the extracellular space. This approach is only feasible
for NCLs caused by defects in soluble lysosomal enzymes (CLN1, 2, 5,
and 10). Non-neuropathic Gaucher disease was the ﬁrst LSD to be suc-
cessfully treated using ERT, however, neurological symptoms were not
successfully treated [77]. This approach has been replicated for treat-
ments in other metabolic disorders, including Fabry disease [54],
mucopolysaccharidosis [100], and Pompe disease [91]. These studies
highlight ERT to be highly beneﬁcial for the treatment of peripheral
symptoms but have yet to show clinical beneﬁt for CNS pathologies,
thought to be due to lack of protein transfer through the blood–brain
barrier.
In vitro experiments have provided proof of principle for ERT in the
NCLs. CLN2 patient-derived ﬁbroblasts exposed to human TPP1 (CLN2)
enzyme showed a restoration of TPP1 activity and a reduction of subunit
c accumulation within the cells [51]. A series of CLN2 mice, mutated to
express varying levels of CLN2, demonstrated that restoration of enzy-
matic activity to an achievable, 3% of that of the normal rate is sufﬁcient
to delay disease onset and a 6% restoration was the benchmark for ‘dra-
matically attenuated disease’ [85].
A strategy, to avoid inaccessibility of the BBB, is to deliver enzymedi-
rectly to the CNS via the ventricular space or parenchyma. Trials in a ca-
ninemodel of MPSI showed reduced lysosomal storage after intrathecal
enzymedelivery via distribution of recombinant enzyme in the cerebro-
spinal ﬂuid (CSF) [35]. Intraventricular delivery of TPP1 to a LINCL
mouse model also resulted in decreased storage material, glial activa-
tion and resting tremor. Detection of TPP1was veriﬁed in the peripheraltissues suggesting CNS administration has the potential to indirectly
rescue peripheral pathologies [9]. Both trials conﬁrmed that intrathecal
delivery is a feasible, alternative option to highly invasive parenchyma
injections
Enzyme replacement therapy is currently the focus CLN2 human
clinical trials. A trial investigating the distribution and safety of recom-
binant TPP1 (rhTPP1. BMN 190) by intracerebroventricular (ICV) deliv-
ery in the CLN2 Dachshund model revealed reduced accumulation of
storage materials and widespread activity of rhTPP1 throughout the
CNS. Brain morphology, neurological function, histopathology, and CSF
andplasma kineticswere attenuated followingBMN190 administration
[37]. This positive outcome has led to the initiation of BMN 190 ICV ad-
ministration studies in humanCLN2 patients (Clincaltrials.gov identiﬁer
NCT01907087). The trial aims to evaluate the safety, tolerability, phar-
macokinetics and efﬁcacy of regular BMN 190 infusions for CLN2 dis-
ease. Preliminary data reported from this ongoing study [5] showed
that nine patients treated with BMN 190 for at least six months showed
a stabilised disease course in terms of motor and language retention
when compared to their natural history control counterparts. Of these
nine patients, six showed no net change in their CLN2 disease rating
score over the six to ﬁfteen months of treatment. Seven of the patients
were examined for walk/talk test scores. All seven patients, following
six months BMN 190 treatment, had better walk/talk test scores than
the natural history control patients. Complete results for all 24 patients
are expected by late 2015.
In addition to the studies of CLN2, preclinical studies involving en-
zyme replacement for CLN1 disease have been reported [31,56] and
would be feasible for CLN5 and CLN10 disease as appropriate sheep
and mouse models are available. Although a promising premise, if ERT
is to become a viable strategy for treatment of NCLs involving a soluble
protein defect, the logistics of repeated administration, delivery to a
larger brain area, effects of long-term use and development of
neutralising antibodies that would decrease the effectiveness of therapy
need to be clariﬁed.
3.3. Stem cell therapy
Stem cell therapies, including bone marrow transplantation and
stem cell transplantation, rely on the rationale that the transplanted
stem cells from a healthy donor will migrate to the CNS, provide a
source of functional protein/enzymeand/or differentiate into the appro-
priate tissue type. Stem cell therapy offers the potential to regenerate
lost tissue alongside neuroprotection — a major advantage for diseases
that have often progressed signiﬁcantly before effective diagnosis.
With established safety proﬁles and success in numerous animal
models, stem cell therapy provides an attractive avenue in NCL treat-
ment development.
3.3.1. Haematopoietic stem cells
Haematopoietic stem cell transplantation is recommended for se-
lected patients with lysosomal storage diseases that affect the brain
and are caused by deﬁciencies in soluble lysosomal enzymes [6]. Unfor-
tunately, this approach has shown showed limited or no success in the
NCL forms in which it has been applied. Haematopoietic stem cell
(HSC) transplantation was performed to normalise PPT1 activity in
INCL patients [55]. This was based on the hypothesis that donor-
derived HSCs are precursors to microglial cells in the CNS, thereby
allowing HSCs to act as a carrier of the correct enzyme for CNS delivery.
PPT1 activity was normalised in circulating peripheral leukocytes, yet
activity of PPT1 in the cerebrospinal ﬂuid remained low in all patients,
except one who showed relatively normal levels ﬁve years post trans-
plantation [55]. All patients suffered severe disease associated neurolog-
ical disability by two to three years of age, with an extremely modest
amelioration of clinical disease course in some subjects following stem
cell transplantation [55]. Reports of HSC transplantation in patients
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[47].
3.3.2. Neural stem cells
Important clinical trials involving neural stem cells have recently
been completed in CLN1 and CLN2 NCL patients. Neural progenitor
cells have the potential to differentiate into neurons or glia and to in-
tegrate with the host CNS upon transplantation.
This rationale behind these trialswas based on the transplant of neu-
ral progenitor cells (NPCs) secreting the functional version of the miss-
ing enzyme into PPT1 deﬁcient mice [92]. In mice, transplants resulted
in successful cell engraftment, migration throughout the brain, continu-
al secretion of the appropriate enzyme and a prolonged survival of host
cell endogenous neurons post-transplant. As expected, PPT1 secreted by
the transplanted cells was shown to be internalised by neighbouring
cells, allowing protection via cross-correction, associatedwith a promis-
ing decrease in autoﬂuorescent storage material [92].
A 2006–2009 phase 1 clinical trial evaluated the safety and tolerabil-
ity of stem cell transplantation (ClinicalTrials.gov identiﬁer
NCT00337636), directly into the brain, for two INCL and four LINCL pa-
tients. Criteria for enrolmentwere that subjects display awell-advanced
stage of disease. Whilst being an effective study to test safety it offered
little chance of measuring clinical improvements.
This trial represented the ﬁrst human use of allogenic foetal neural
stem cells (HuCNS-SC) for the treatment of a neurodegenerative dis-
ease. HuCNS-SC were transplanted into the cerebral hemispheres and
lateral ventricles of the subjects, followed by 12months of immunosup-
pression. Complications that occurred during the trialwere attributed to
normal disease progression or immunotherapy agents, with no evi-
dence that problems were a result of the HuCNS-SCs.
Post-mortem analysis in 2/3 patients showed evidence of donor cell
engraftment and cell migration from the initial transplantation site 357
and 918 days post transplantation. The failure to conﬁrm donor cells in
the third patient was attributed to low dose immunosuppression and
host-activated microglia [83].
Early stages are encouraging, however, it is unknown exactly how
protection is mediated, as many HuCNS-SCs did not differentiate into
neurons. If cells are only capable of enzyme secretion and limited in
terms of neuronal replacement this would mean the therapy could
only be effective if delivered early on in the disease course as a
neuroprotectant as well as only being applicable for soluble protein
NCL disease forms.
In conclusion the trials demonstrated a high level of tolerability and
HuCNS-SCs proved capable of providing a long-lasting supply of en-
zyme, encouraging future studies using HuCNS-SCs.
3.4. Gene therapy
A promising treatment option for all forms of NCL is viral-
mediated gene therapy in which a cDNA encoding wildtype protein
(e.g., CLN2) is packaged into lentiviral or adeno-associated viral
(AAV) particles. These are then injected into the CNS of patients in
the hope that the corrected version will be expressed in the trans-
duced cells, thereby restoring protein function. Gene therapy offers
the potential for a permanent cure that does not require lifelong re-
peated treatments. This is a key advantage over transient therapies,
and especially valuable in NCL treatment, as repeated intrusions
into the fragile brain of a patient could induce further damage.
Gene therapy strategies for the NCLs need to consider whether the
mutated protein is soluble or membrane-bound. Viral mediated gene
therapy relies on a small population of cells receiving the normal copy
of the gene, then over-expressing the gene product and secreting the
protein for uptake by neighbouring cells; a process known as cross-
correction (reviewed in [76]). As discussed above, CLN1, CLN2, CLN5
and CLN10 are secreted from cells so are compatible with such a
cross-correction approach. The NCLs deﬁcient in membrane-boundproteins will be more difﬁcult, but not impossible, to develop a gene
therapy, as a signiﬁcantly higher proportion of cells must be transduced.
Current pre-clinical and clinical trials of gene therapy in NCLs use
adeno-associated viral or lentiviral derived vectors for gene delivery.3.4.1. Adeno-associated viral vectors
Adeno-associated viruses (AAVs) are single-stranded DNA viruses
from the Parvoviridae family. Recombinant AAVs have a number of qual-
ities that make them highly appealing in the ﬁeld of gene therapy. First-
ly, many serotypes of AAVs from multiple host species have been
identiﬁed, each presenting unique tropisms for different tissue
types — allowing tissue and cell speciﬁc targeting of the vector. For ex-
ample, AAV2 demonstrates natural tropism towards neurons over other
cells— a candidate for NCL therapy. Secondly, AAVshave reportedwide-
spread distribution of the vector in the CNS via axon transport, increas-
ing the range of transduction after initial introduction. Finally, AAVs
present tropism for post-mitotic long-lived tissue. Recombinant AAV re-
mains predominantly episomal, signiﬁcantly reducing risk associated
with integration into key genomic sites in host cells. Enduring episomal
maintenance and expression in non-dividing cells precludes the need
for constant dosing and potentially lethal CNS complications.
The main hurdle with AAV use is the induction of immune response
[63]. AAVs low level of immunogenicity is associatedwith small titres of
neutralising antibodies (NAb), which, whilst are generally considered
safe, could interfere with efﬁciency of gene transfer [62]. Studies in
both healthy and cystic ﬁbrosis affected subjects reveals that most indi-
viduals harbour antibodies against AAV2, derived from naturally occur-
ring previous exposure to these viruses [12]. The presence of these
antibodies elicits a humoral immune response in a signiﬁcant propor-
tion of healthy individuals, further increasing the challenge of successful
gene transfer [60]. The degree of this immune response to AAV vectors
is believed to differ based on the route of administration [7,61]. Data is
still limited with regards to how this immune induction will affect
transgene expression in the central nervous system. However, it is
suspected that no immune responses arise in response to the transgene,
allowing expression in the target tissue [13,30]. Repeated injection of
AAV with the same or different transgenes into the rat brain shows a
low immunological response, with repeated expression and successful
transgene expression possible [61]. Further investigation is required to
properly understand the signiﬁcance and implications of the efﬁcacy
and toxicity of AAV-triggered immune responses.3.4.2. Lentiviral vectors
LVs are single-stranded RNA viruses of the Retroviridae family. A
major advantage for LV, over AAV is the capacity for packaging
(10 kb in LV versus 4.8 kb in AAV). LV also exhibit a low level of im-
munogenicity and initiation of systemic immunity [1]. This in-
creases safety and maintains the efﬁcacy of the virus if repeatedly
administration is necessary. LVs do not display tissue-speciﬁc tro-
pism, however they can be pseudotyped via alteration of envelope
proteins, usually with the vesicular stomatitis glycoprotein [16]. To
allow the transgene to be expressed, LVs integrate into the host
genome. This integration is effective at producing persistent
expression in dividing cell populations. However, nonspeciﬁc inte-
gration, especially in areas that are actively replicating, could cause
unintended serious consequences [25]. Non-integrating LV vectors
are currently under development, in order to avoid insertional mu-
tagenesis by maintaining episomal expression [64,70,72]. In addi-
tion, traditional lentiviral vectors show no anterograde or
retrograde transport and therefore transduction is limited to the
site of injection [53]. Modiﬁcation of the envelope to contain chi-
meric rabies glycoproteins results in signiﬁcant retrograde trafﬁck-
ing [36,78], however this does not compare to trafﬁcking efﬁcacy of
some of the AAV serotypes.
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Gene therapy treatments have also been tested in mouse models of
CLN1, 2 and 10, to determine the feasibility of vector-mediated gene
transfer prior to progression into human patients, especially in disease
variants that lack a large animal model.
3.5.1. CLN1
CLN1 disease, or INCL results in a deﬁciency of PPT1. Murinemodels
of INCL have demonstrated decreased storage material, and partial in-
crease in brain weight and cortical thickness, when treated with an in-
tracranial AAV2-PPT1 injection. Initially promising, these experiments
showed negligible improvement in life-span [22,24]. However, when
combined with bone marrow transplantation (which alone is ineffec-
tive) AAV2/5-PPT1 gene therapy resulted in a dramatic improvement
in lifespan from around 6 to 18 months [58]. AAV2-PPT1 expression
has also been delivered intravitreally, in an attempt to improve ocular
function in INCL [23]. Increased PPT1 activity resulted in decreased pho-
toreceptor loss and an increase in degree of organisation in the outer
nuclear layer. Interestingly, a decrease in neurodegeneration occurred
at distal sites in optic tracts suggesting PPT1 is also transported into
the brain via axons along visual pathways.
Complementing viral mediated gene therapy with small molecule
drugs, provided evidence towards PPT1 combination therapy providing
a clinical beneﬁt. PPT1−/−mice were treated with CNS-directed AAV2/
5-PPT1 and systemic-directed, lysosomotropic, PPT1 mimetic,
phosphocysteamine. This resulted in an additional though modest im-
provement in motor function in comparison to individual therapies
[75].
These studies concluded that AAV-PPT1 demonstrates extensive en-
zyme correction in the cortex and hippocampus, yet highlighted the
need for wider expression of the enzyme in regions, such as, the cere-
bellum, if gene therapy is to be efﬁcacious against CLN1 disease.
3.5.2. CLN2
The effectiveness of viral mediated delivery of the TPP1 (CLN2) gene
into the mouse CNS was ﬁrst tested using TPP1 expressing vectors: re-
combinant adenovirus (Ad), feline immunodeﬁciency virus (FIV), and
adeno-associated virus (AAV5), via single injections into themouse stri-
atum and cerebellum. Ten days post-injection, TPP1-positive cells were
observed around the injection site, corpus callosum, choroid plexus, and
ependymal layer. TPP1 enzyme activity in brain homogenates was
three- to seven-fold higher in the injected hemispheres, compared to
endogenous levels [29]. Following the development of a CLN2 mouse
model [86] the efﬁcacy of AAV2 and AAV5-CLN2 vectors in the correc-
tion of cellular pathologies was demonstrated [67]. The limited spread
of these serotypes requires multiple injection targets even in the small
rodent brain. Conversely, AAVrh10 derived from a rhesus macaque
spread widely throughout the CNS and mediated both cellular, behav-
ioural correction and increased lifespan [87]. These data, together with
large animal studies in non-human primates, have formed the basis
for ongoing human clinical trials.
3.5.3. CLN10
A CtsD deﬁcient murine model of NCL was treated, to induce re-
expression of CtsD, with AAV2-CtsD vectors via either CNS or peripheral
application, or both combined [84]. Forebrain application resulted in re-
duced storagematerial, microglia activation, a doubled life span and im-
provements in visceral organ pathologies. Peripheral application
resulted in improvements to visceral integrity, but has no effects on
the CNS and no improvement in life-span in comparison to untreated
littermates. Combined application showed a similar effect to that of
forebrain delivery with an increased lifespan up to four times that of
their WT littermates. The disease was shown to return in CNS, and
CNS-periphery combined, treated mice. A sudden reoccurrence of pe-
ripheral pathologies, such as atrophy of the liver and spleen, wereobserved at ~60 days after initial application, resulting in death. At the
time of death the CNS was validated as intact, in comparison to the un-
treated mice, implicating something other than neurodegeneration and
microglia activation in the death of CtsD deﬁcient mice.
3.6. Gene therapy trials in large animal models
Gene therapies are best developed in large animalmodelswith com-
plex, human-like brains, thus making the ovine and canine models a
highly valuable resource.
3.6.1. CLN2
Following positive mouse model studies, dose and safety proﬁles for
the AAVrh10hCLN2 vector were established in non-human primates
[88]. Eight African greenmonkeyswere administered theAAVviral con-
struct at a dose scalable to humans. The AAV treated monkeys showed
no deviations to untreated controls under any tested safety parameter,
with the exception of mild to moderate white matter inﬂammation
around the injection site. The TPP1 transgenewas shown to have wide-
spread distribution throughout the non-human primate brain. Togeth-
er, these data conﬁrmed the potential beneﬁt of AAVrh10 mediated
therapy in human patients. AAV-mediated gene therapy is also ongoing
in a dog CLN2 model. This study demonstrated improved motor and
cognitive functions and increased lifespan compared to untreated
dogs [94].
3.6.2. CLN5/6
In addition to AAV2 and AAVrh10 trials, a cohort of CLN5−/−
Borderdale and CLN6−/− South Hampshire sheep at Lincoln University
have been treated with CLN5 or CLN6 protein expressed via lentiviral
or adeno-associated (AAV9) viral vectors. Disease onset and progres-
sion are being monitored in these sheep, including CT scans to deter-
mine total brain volume. Behavioural analyses (vision, cognitive score,
maze navigation) are also ongoing to determine if the viral-mediated
CLN-protein overexpression is sufﬁcient to delay or halt disease pro-
gression (personal communication, Mitchell, Palmer, and Hughes).
Cumulatively, these animal studies highlight the feasibility of gene
transfer as a potential NCL treatment, and provided an important
stepping-stone towards human trials.
3.7. Clinical trials in gene therapy
Human gene therapy clinical trials have been conducted in patients
with CLN2 disease. Ten children with LINCL were administered with a
CLN2 cDNA-containing AAV2 virus into twelve cerebral locations.
Post-surgery, the rate of neurological decline between treated and un-
treated patientswas determinedby a neurological rating scale andmag-
netic resonance imaging [99]. Neurological decline was signiﬁcantly
reduced in the treated patients as compared to theuntreated control pa-
tients. No adverse effects relating directly to the viral vector itself were
apparent post-surgery. However, serious events included the death of a
patient 14 days post-surgery after the development of status epilepticus
[99]. This small trial suggested a delay in disease progression, rather
than a complete halt in pathology, after viral administration.
In a similar phase I clinical trial of ten patients, CLN2-containing
AAV2 vector was injected into twelve cerebral locations over six entry
sites. Post-surgery, 65% of the injection sites showed evidence of viral
localisation and infusion by MRI [89].
Two separate clinical trials are currently underway using the
AAVrh10-TPP1 experimental therapy. One trial is recruiting patients
with the ﬁve most common LINCL/CLN2 genotypes (ClinicalTrials.gov
identiﬁer NCT01161576), whereas the parallel second trial has in-
creased the inclusion criteria to any patient with CLN2 disease
(ClincalTrials.gov identiﬁer NCT01414985). The primary aims of these
studies are to assess the safety and tolerability of patients to treatment,
Table 3
Major recent/ongoing clinical trials in the NCLs.
NCL
subtype
Treatment approach Status Sponsor/location
CLN1 Stem Cell Therapy (NCT00337636) Completed StemCells, Inc.
Small Molecule, Cystagon
(NCT00028262)
Completed NICHD
CLN2 ERT with BMN-190 (NCT01907087) Active BioMarin
AAVrh.10CUhCLN2 (NCT01414985) Recruiting WCMC
AAV2CUhCLN2 (NCT01161576) Active WCMC
Stem Cell Therapy (NCT00337636) Completed StemCells, Inc.
CLN3 Small Molecule Therapy —
Mycophenolate mofetil (NCT01399047)
Recruiting University of
Rochester
WCMC — Weill College of Medicine, Cornell University.
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ment efﬁcacy.
3.8. Prospects for gene therapy
Viral mediated therapy is currently ineffective at delivering protein
to all brain regions, resulting in the need formultiple sites of therapeutic
injection. This is due to both the size of the human brain and the high
level of protection to external inﬂuence by the blood–brain barrier
(BBB).
Currently, the main problemswith viral-vector mediated gene ther-
apy are biodistribution, immune response and method of delivery. Op-
tions to improve distribution and delivery include the use of modiﬁed
AAVs expressing disease-speciﬁc epitopes [11], and reducing the pro-
duction of neutralising-antibodies in response to the vector. Increasing
the range and accuracy of distribution should negate the need for as nu-
merous and/or frequent CNS intrusions.
A recent study [21] in a mouse TPP1−/−model utilised mannitol to
osmotically disrupt the BBB, in an attempt to allow intra-arterial (IA)
administration of AAVrh.10CLN2. After IA mannitol administration,
AAVrh10.CLN2 was administered, also via IA injection, into arteries
leading to the brain. This resulted in widespread TPP1 expression, in
neurons and glia, diffusely throughout the cerebral hemispheres after
a single administration. This exciting result shows BBB disruption
could represent a viable viral-mediated, gene-therapy option, although,
the implications of disrupting the protection around an NCL patients
brain must be thoroughly investigated prior to commencement of
human trials.
Future prospects in this area of clinical investigation includeprenatal
gene therapy and gene editing technologies. Prenatal gene therapy of-
fers several potential advantages for CNS therapy; long term expression
of the gene product in post-mitotic cells, potential for transduction of
stem and progenitor cells, induction of immune tolerance to the
expressed protein, and the potential to treat the disease at the earliest
possible stage [71]. However, in terms of recessive conditions such as
the NCLs, a treatment of this type would not be possible in themajority
of cases where family history has not been established.
Gene editing is still in its infancy, yet has the exciting potential to
permanently ﬁx a speciﬁc mutation to result in endogenous restoration
of protein activity within the patient. This could not only mitigate the
need for life-long treatment, but also avoid adverse effects of protein
overexpression that could happen with other, for example viral, gene
therapy methods. Gene editing has recently experienced a ‘resurgence’
of interest after the discovery of the CRISPR–Cas system. This system,
derived from bacteria, enables single base-pair modiﬁcations with
greater reported simplicity and decreased expense over other well-
known gene editing systems; ZFNs and TALENs.
One exciting aspect of the increasing understanding of these sys-
tems, is the ability to converge these editing technologies with patient
derived hiPSCs to treat diseasewithout the risk of immune rejection. Re-
cently, CRISPR-Cas and ZFNs have been used in iPSC cells to ﬁx the beta
globin gene mutation in sickle cell anaemia [20,81] Other promising
gene-editing work shows the ability of CRISPR to remove HIV from
the genome [40,102], correct a mouse model of human hereditary
tyrosinemia [101] and produce transgenic animal models [57] at a
greater speed than comparative methods.
Gene-editing for Batten disease, via in vivo gene editing or in-direct
in vitro iPSCs editing, would be of great advantage, over other therapies,
as it could mitigate the need for repeated intrusions into the patient's
brain. Potential problems associated with this therapy include off-
target gene editing and the issue of ﬁnding the percentage of gene cor-
rection needed to prevent disease phenotype. Every form of Batten dis-
ease would require the careful selection of unique targets and, most
likely, require different therapeutic approach dependent on whether
the corrected protein can ‘cross-correct’ other cells. Although several
groups have made encouraging progress in the treatment of disease,via gene editing, there is currently no evidence of therapeutic success
in neurological disease.
Data regarding the success and usefulness of current viral-mediated
gene therapy technologies as a therapeutic strategy for the NCLs will in-
crease in the near future, as the current clinical trials reach completion.
4. Summary of progress in clinical trials
Table 3 outlines themajor efforts currently underway in various NCL
subtypes, highlighting the major studies of discussion in this review.
Human clinical trial information was obtained from ClinicalTrials.gov.
5. Hurdles and promise on the horizon
Therapies for the NCLs are closer to reality, with pre-clinical trials
using ERT and gene therapy proving positive in animalmodels. New ap-
proaches and improvements on current strategies will continuewith an
increased understanding of the NCL proteins and their role in normal
brain function. Protein replacement strategies using ERT or gene thera-
py must take into account the issue of immune responses to protein
and/or vector because understanding and mitigating these effects are
critical to successful treatments. Combining these protein replacement
therapies with small molecule drugs may provide the greatest beneﬁt.
However, by extending the life expectancy of patients, through attenu-
ation of neurological symptoms, further pathologiesmay arise in thepe-
ripheral organs; including the heart [90], and these pathologies need to
be examined further.
Animalmodels, both small and large have provided valuable insights
into both biology, pathology and treatment strategies. Once effective
therapies are available, newborn screening for NCLs will be realistic
and necessary to prevent or reduce the burden of these devastating dis-
eases. In summary, the future of treatment design for NCL disease
should be aimed at treating patients in the early stage of disease, via a
method that requires as little invasion into the CNS as possible. These
therapies should also be tested where possible on large animal models
before application to humans as a vital prerequisite in identifying po-
tential problems and solutions.
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